Bill > B26-0654

This bill, the Medical Cannabis Beverage Product Amendment Act of 2026, aims to expand the District of Columbia's medical cannabis program by creating new licensing endorsements and clarifying existing regulations. It introduces a "medical cannabis beverage production endorsement" allowing certain licensed alcohol manufacturers to produce non-alcoholic medical cannabis beverages using cannabis or THC (tetrahydrocannabinol) provided by a licensed medical cannabis manufacturer, with strict requirements for delivery back to that manufacturer and adherence to testing and tracking rules. The bill also establishes a "medical cannabinoids import endorsement" for licensed medical cannabis manufacturers or cultivation centers to import cannabinoids (chemical compounds from cannabis or hemp, or synthetically produced ones) from approved sources, provided they meet specific safety and testing standards and contain no THC, for use in producing medical cannabis products. Furthermore, it clarifies that licensed couriers can transport these new types of medical cannabis products between relevant licensed entities, and it ensures that the existing 6% gross receipts tax rate applies to both medical cannabis and medical cannabis products.

https://lims.dccouncil.gov/Legislation/B26-0654